Trevi Therapeutics (TRVI)

• Market cap: $1.29B
• 1 day: -2.48%
• 5 days: 1.53%
• 1 month: 26.73%
• 3 months: 34.6%
• 6 months: 69.38%
• Year to date: 143.58%
• 1 year: 230.84%
• 5 years: 205.17%
• 10 years: 34.6%
• Sector: Healthcare
• Industry: Biotechnology

About: Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.

Employees: 33